Abiraterone

Metastatic castration-resistant prostate cancer is the main subtype of advanced prostate cancer, and patients have long faced the clinical dilemma of limited survival benefit after endocrine therapy resistance. As an irreversible inhibitor of CYP17A1 and an androgen biosynthesis inhibitor, abiraterone can block the androgen synthesis pathway in the testes, adrenal glands and prostate tumor tissues, and continuously reduce the androgen level in patients without chemotherapy. It is often used in combination with prednisone in clinical practice, and is indicated for patients with metastatic castration-resistant prostate cancer and newly diagnosed high-risk metastatic endocrine therapy-sensitive prostate cancer. It is one of the core therapeutic drugs for the advanced stage in the current whole-course management of prostate cancer.

At present, the global market size of abiraterone has exceeded 3 billion US dollars, and the market size in China has exceeded 4.5 billion yuan. Against the background of the rising incidence of prostate cancer year by year, the overall market maintains a compound annual growth rate of about 8%. In terms of competitive landscape, the original research product accounts for nearly 4+X

The original research enterprise is Johnson & Johnson, and the original research trade name is Zytiga. The expiration date of its core compound patent in China is 2022. The main dosage form of the original research product is tablet, with specifications of 250mg and 500mg, which has been included in the *Catalogue of Chemical Drugs* of China and the FDA Reference Listed Drug Catalog. In China, at present, abiraterone API from more than 30 enterprises have been approved for registration and publicized on the CDE API registration platform, and abiraterone acetate tablets from more than 20 enterprises have been approved for marketing.(Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for abiraterone API. Most products are in regular stock. For in-stock products, delivery can be arranged on the same day if the order is placed before 16:00. All impurity reference standards fully meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and meet the impurity research needs of enterprises.

CATO/佳途科技可提供阿比特龙API全套杂质标准品，多数产品常备现货供应，现货产品16:00前下单当日即可安排发货，所有杂质对照品全面符合中国药典、FDA等多法规体系要求，满足企业杂质研究需求。